Study of hs-CRP, Blood Glucose and Blood Pressure to evaluate the risk of Nephropathy in type 2 Diabetes

Authors

  • Jay Prakash Sah Pokhara University
  • Chandrakant Yadav Pokhara University, Lekhnath-12, Kaski, Nepal
  • Dipendra Kumar Yadav Pokhara University, Lekhnath-12, Kaski, Nepal
  • Sapana Subedi Pokhara University, Lekhnath-12, Kaski, Nepal
  • Sujana Neupane Pokhara University
  • Sangita Pandey Pokhara University

DOI:

https://doi.org/10.37628/ijbb.v1i1-2.6

Keywords:

Blood Pressure, Diabetic Nephropathy, Fasting blood Glucose, High sensitivity-C reactive protein

Abstract

Diabetes nephropathy is an emerging serious health problem for diabetic patients. Many studies have demonstrated that high-sensitive C-reactive protein (hs-CRP is a marker of inflammation. It may play a significant role as predictor of inflammation in nephropathy patients when it could test with other reliable marker. The aim of present study was to estimate the association among hs-CRP levels, fasting blood glucose and blood pressure level. A quantitative, analytical, hospital-based study was done by enrolling 89 type-2 diabetic patients conducted at Tertiary Care Hospital. The authors analyzed serum concentrations of hs-CRP, fasting blood glucose and blood pressure of type-2 diabetic patients. In this study, the authors found the significant association between serum hs-CRP and fasting blood glucose level (P values = 0.001). Furthermore, serum hs-CRP was not correlated with blood pressure (P > 0.161). In the same way, fasting blood glucose was not also significantly correlated with blood pressure of diabetic patients. This study concludes that serum hs-CRP value in type-2 diabetic patients is significantly correlated with fasting blood sugar level. And there is no correlation of both serum hs-CRP and fasting blood glucose level with the risk factors especially blood pressure of type-2 diabetes. The significance of these findings emphasizes to choose these associations for early screening and staging of diabetic nephropathy.

Author Biographies

  • Jay Prakash Sah, Pokhara University
    SHAS, Assistant Professor
  • Chandrakant Yadav, Pokhara University, Lekhnath-12, Kaski, Nepal
    SHAS, Laboratory Demonstrator
  • Dipendra Kumar Yadav, Pokhara University, Lekhnath-12, Kaski, Nepal
    SHAS, Assistant Professor
  • Sapana Subedi, Pokhara University, Lekhnath-12, Kaski, Nepal
    Department of Medical Laboratory Science, SHAS
  • Sujana Neupane, Pokhara University
    Department of Medical Laboratory Science, SHAS
  • Sangita Pandey, Pokhara University
    Department of Medical Laboratory Science, SHAS

References

Kasper DI, Fauci AS, Hauser SL, Longo DL, Jameson JL. Harrison's Principles of Internal Medicine 3. 2005;16(3).

Agarwal N, Sengar NS, Jain PK, Khare R. Nephropathy in Newly Diagnosed Type 2 Diabetics with Special Stress on the Role of Hypertension. Association of Physian India. 2011;59:145-47.

Nepal Diabetes association (NDA). Annual report. 2013.

American Diabetes Association. Nephropathy in diabetes (Position Statement) Diabetes Care. 2004;27(1):79-83.

Crook M. Type 2 diabetes mellitus: a disease of the innate immune system? An update. Diabet Med. 2004(21):203-7.

Dalla VM, Mussap M, Gallina P. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol. 2005(16):78-82.

Martha RM , Fernando GR. Increased levels of CRP in Non-controlled Type II diabetic subjects. Journal of Diabetes and its complications. 1999(13): 211-215.

Blake GJ. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. Journal of the American College of Cardiology. 2003;41(4):37-42.

Wang CH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, Li RK, Mickle DA, Verma S. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth musles. Circulation. 2003(107):1783-90.

Pasceri V WJYE. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000(102):2165-8.

Venugopal SK, Yuhanna I, Shaul P. Demonstration that C reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002(106):1439-41.

M B. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-20.

M C. Pathogenesis, prevention and treatment of diabetic nephropathy. Lancet. 1998.

Pepys MB. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805-12.

Bhattarai MD SD. Learning the lessons – preventing type 2 diabetes in Nepal. Diabetes voice. 2007;52(2):9-10.

Choudhury TA LS. Complications and cardiovascular risk factors in South Asians and Europeans with early-onset type 2 diabetes. QJM. 2002;95:241-6.

Urooj Taheed Baluch IGK, Niazi R, Nighat B, Tahir F. C- Reactive Protein As A Low Grade Inflammatory Marker in type 2 diabetic nephropathy. Ann Pak Inst Med Sci. 2011;7(4):217-21.

Liu F CH, Huang XR, Chung AC, Zhou L, Fu P. C-reactive protein promotes diabetic kidney disease in a mouse model of type 1 diabetes. Diabetologia. 2011;54:2713-23.

Sugam S, Shrestha R, Poudel B, Sigdel M. Serum Urea and Creatinine in Diabetic and non-diabetic Subjects. Journal of Nepal Association for Medical Laboratory Sciences. 2008;9(1):11-2.

Mittal A SB, Kumar A, Chandrasekharan N, Sunka A. Diabetes mellitus as a Potential Risk Factor for Renal Disease among Nepalese. Nepal journal of Epidemiology. 2010;1(1):22-5.

Jiji Inassi VR. role of duration of diabetes in the development of nephropathy in type 2 diabetic patients. National Journal of Medical Research. 2013;3(1):1-8.

Chen-Chung F Y-ML, Jer-Chuan Li1, Du-An Wu. Association of C- reactive Protein and Traditional Risk Factors with Nephropathy in the Elderly Patients with Diabetes. Taiwan Geriatrics & Gerontology.3:202-10.

Khalaf SJ. Study of some biochemical markers in diabetic patients. Tikrit Medical Journal. 2010;16(2):84-7.

Sun H, Koike T, Ichikawa T. C-reactive protein in atherosclerotic lesions: its origin and patho-physiological significance. American Journal of Pathology. 2005; 167(4): 1139–48.

Sacks DB, Bruns DE, Goldstein DE, Maclaren NK. Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Clin Chem. 2002;48(3):436-72.

Azza ME, Tarek MA, Rizk AE, Wafaa AM. Role of hypertension and metabolic abnormalities in the development of diabetic nephropathy among Egyptian patients with type 2 diabetes. Nature and Science 2011; 9(7):220-8.

Kaefer M, Piva SJ, De-Carvalho JA, Da- Silva DB, Becker AM, Coelho AC, Durate MM, Moresco MN. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. clin biochem. 2009.

Mojahedi MJ, Bonakdaran S, Hami M, Sheikhian MR, Shakeri MT, Aiatollahi H. Elevated Serum C-Reactive Protein Level and Microalbuminuria in Patients With Type 2 Diabetes Mellitus. Iranian Journal of Kidney Diseases .2009;3:12-6.

LING Yan, LI Xiao-mu and GAO Xin. Cross-sectional association of serum C-reactive protein and uric acid with albuminuria in Chinese type 2 diabetic patients. Chinese Medical Journal. 2013;126 (21):4023-29.

Kanga ES, Kimb JH, Ahna CW, Parkc CW, Chaa BS, Lima SK, Kima KR, Leea HC. Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes. Diabetes Research and Clinical Practice. 2005:151–59.

Mohan K, Sultana M.Studies on serum lipids, lipoproteins and high sensitive C-Reactive protein in type 2 diabetes. Indian Journal of Science and Technology. 2011;4(3):185-91.

Downloads

Published

2016-05-09

Issue

Vol. 1 No. 1-2 (2015)

Section

Articles